Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930625 | 0.87 | RORB (0.47) | HCRTR1HCRTR2TRPV1PARP1KIF11 | |
| SCHEMBL2931039 | 0.87 | HCRTR2 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL2925368 | 0.86 | HCRTR1 (0.41) | HCRTR1HCRTR2CHRNA7TRPV1S1PR5 | |
| SCHEMBL2925421 | 0.85 | CFD (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL2933413 | 0.85 | RORB (0.38) | HCRTR1HCRTR2CHRNA7TRPV1JAK2 | |
| SCHEMBL2924242 | 0.85 | FABP4 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL2930073 | 0.85 | PDE4B (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL2928147 | 0.84 | HCRTR1 (0.36) | HCRTR1HCRTR2CHRNA7 | |
| SCHEMBL2933638 | 0.83 | NPC1 (0.39) | HCRTR1HCRTR2TRPV1PARP1 | |
| SCHEMBL2931912 | 0.82 | APOB (0.38) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885CHRNA7 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.